read
water open earn life scienc tool coverag clean top-
line beat revenu came expect organ growth drive
beat fundament deliv strong result
pharmaceut end market constant currenc growth import
driver thesi addit return strength grow organ
encourag data point follow mute start
despit overal strong top-lin perform surpris see
mute oper leverag particularli sg line lack leverag led
weak ep beat quarter adjust ep beat expect
aid increment tax benefit stock-bas comp
fx benefit technic core miss adjust
impact revenu would come low end guidanc
estim despit better top line perform believ factor
led under-perform follow earn call share vs
water initi guidanc appear reason revenu ep
bracket expect compani also weigh tax reform
solidifi view water net beneficiari due repatri
still screen upsid model organ revenu growth expect mid-
singl digit assum line prior current forecast ep
anticip rang prior estim
midpoint tax reform optimist around increas flexibl use
oversea cash enhanc innov optim balanc sheet return capit
sharehold reform expect headwind statutori tax rate
continu believ better access oversea cash
make overal net posit reiter equal weight rate
water view compani fairli valu ebitda
action rais price target
quarterli annual ep usd
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
equal weight admir track
record above-market revenu growth margin
given compani market domin
pharmaceut custom chromatographi
said balanc water success view
difficult gener sustain above-
market earn growth reflect
biopharma remain area strength higher
consum margin drive upsid
ebitda expect upsid ebitda
million yield upsid case
fund biotech pressur capit invest
life scienc tool drive downsid
ebitda estim downsid ebitda
million yield downsid case
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
water open earn life scienc tool coverag clean top-lin
beat revenu came expect organ growth drive
beat fundament deliv strong result pharmaceut end market
constant currenc growth import driver thesi addit
 return strength grow organ encourag
data point follow mute start despit overal strong top-lin
perform surpris see mute oper leverag particularli
sg line lack leverag led weak ep beat quarter adjust ep
beat expect aid increment tax
benefit stock-bas comp fx benefit technic core miss
adjust impact revenu would come low end
guidanc estim despit better top line perform believ
factor led under-perform follow earn call share
vs
water initi guidanc appear reason revenu ep
bracket expect compani also weigh tax reform solidifi
view water net beneficiari due repatri still screen
upsid model organ revenu growth expect mid-singl digit
assum line prior current forecast ep anticip
rang prior estim midpoint tax reform
water optimist around increas flexibl use oversea cash enhanc
innov optim balanc sheet return capit sharehold reform
expect headwind statutori tax rate continu believ
better access oversea cash make overal net posit
water reiter equal weight rate water view compani fairli
valu ebitda
rais price target reiter equal weight rate
quarter better visibl growth rais target
multipl ebitda vs previous also model modestli higher ebitda
growth million vs million previous growth remain solid across
product end market categori remain valuat sensit share
trade all-tim high ev ebitda
believ tax reform net posit access oversea
cash billion outweigh neg impact compani non-
tax rate earn call ceo chri oconnel restat compani capit
deploy prioriti invest intern busi optim compani
balanc sheet return capit sharehold comment tax reform
go caus major shift prioriti cite compani take
opportunist approach use avail cash new opportun includ abil
effici invest enabl lower cost capit addit
new access capit allow compani make improv compani
capit structur someth expect result decreas interest expens
oversea
access oversea cash posit anticip tax reform
neg impact tax rate adjust tax rate
reduct corpor tax rate expect benefit
compani non-gaap tax rate benefit expect off-set increas
tax neg impact tax rate compani foreign incom result
intang base broaden provis lower corpor tax rate
compani also realiz modest benefit stock-bas compens
account tax anticip tax rate rang
repres increas y/i compani expect off-set ep
headwind tax share repurchas result guid weight
share outstand million year
post strong quarter biopharma organ growth cite
broad-bas biopharma demand specif strength us china rebound
us pharma driven mid larg pharma custom
conserv spend given potenti polici tax chang slow
us biopharma result improv sequenti year-end give manag
renew sens confid end market china grew double-digit
continu benefit new regulatori requir china fda india growth
rebound follow issu tie implement new gst system
water note strong biopharma demand europ continu driven strength
small molecul well biopharma applic compani well-posit
target lc-m biopharma separ solut overal compani continu
character pharma market healthi posit market trend remark
earn call
water ceo chri oconnel note sale broadli defin pharmaceut
quarter highlight strong demand
pharmaceut custom continu double-digit pharma growth china solid
pharma rebound india full year global sale growth pharma
strong base comparison throughout year
continu see consist sustain result driven increasingli divers base
custom attract geograph balanc strong product posit small
molecul larg molecul medic research applic on-going strategi work
continu emphas vast opportun pharmaceut busi
believ well posit expand core technolog greater
total millionscash oversea total oversea barclay corp
breadth applic meet grow increasingli complex requir
custom
regard pharma ceo oconnel mention encourag
pickup spend mid-size larg pharmaceut custom
cautiou earlier year full year sale america flat
 grow second half growth off-set first half declin ye
said prepar remark encourag know
first half year sustain declin -- pretti clear
time even clear retrospect caution part lot
compani particularli pharma industri busi realli wait
regul polici tax chang came later year
see recal improv third quarter
nice close year would say finish hope
renew sens confid pretti broad-bas way across
end market feel good go year obvious
quarter trend make enter hope also
balanc term might happen
tool average includ agil thermo fisher
follow solid result recent quarter academ govern busi
grew y/i organ quarter strength across major geographi
specif demand driven academ spend biomed omex research
ceo chri oconnel address lumpi academ govern end market
note relat academ fund probabl best proxi
best proxi type question sinc academ govern smaller percentag
busi academ though lion share govern academ
categori good year growth keep mind prior year
declin know busi tend quit lumpi
see decent trend back half year academ world particularli realli
geographi around world never entir clear sustain
look balanc come year sort middl part guidanc
histor kind rang academ type perform
factor point compar academic/govern exposur
mix academic/govern exposur broader mani
peer compani nih busi also dod fbi usda
name gener nih repres academ govern revenu
remaind coverag
academ govern smallest custom class repres
total revenu gener academic/govern custom major util
chromatographi system also mean percentag revenu
consum servic stream lower area instead sale gener
driven high-end mass spectrometri placement lumpi quarterli
basi chromatographi largest product segment monitor
biopharma trend better read segment perform addit
natur market academ govern notabl sticki
trend tend vari per quarter
similarli less consum revenu academic/govern
custom class peer water broad consum stream lab
suppli sampl prep like thermo fisher agil drive consist
govern academ exposur
end market perform quarter
issu initi guidanc revenu expect line model
ep expect bracket prior estim revenu anticip
mid-singl digit organ growth assum impli growth combin
forecast tailwind fx believ expect total
revenu growth gross margin expect rang
midpoint would impli y/i declin net interest expens
expect rang million repres declin million
compani greater flexibl optim balanc sheet
tax reform guidanc assum share count million share buyback expect
off-set neg impact tax reform ep tax anticip
non-gaap tax rate repres increas midpoint
lower tax rate benefit expect off-set high foreign tax
headwind modest benefit tax stock-bas compens
account benefit valu corpor tax rate instead
guidanc call ep rang repres growth
y/i foreign exchang expect neutral ep
market y/i y/i growth y/i y/i growth y/i y/i growth y/i growth barclay corp
guid toward mid-single-digit organ revenu growth
tailwind fx believ impli total revenu growth pencil
revenu million water guid ep rang
due difficult comp benefit stock-bas compens account
water expect non-gaap tax rate increas fx expect
tailwind ep
guidanc
revenu million expect million
constant currenc growth better expect compar
compani guidanc million embed organ growth
fx tailwind revenu repres growth y/i ex-fx total growth
fx tailwind underli growth across product segment solid
quarter import categori improv instrument grew
y/i ex-fx recur revenu grew y/i ex-fx includ growth servic
chemistri
revenu grew organ
water divis revenu organ growth y/i water divis
revenu million came million expect
million increas y/i organ basi revenu increas y/i
estim total compani servic revenu growth came
expect organ growth versu expect chemistri
revenu beat expect versu expect organ
instrument growth better expect currenc
tailwind segment revenu quarter posit rel
expect guidanc call currenc tailwind
ta instrument divis revenu organ growth y/i ta
instrument revenu million came million estim
increas organ y/i currenc tailwind quarter
interestingli water ta instrument segment deliv strong result
quarter broader industri end market deliv flat organ growth
revenueorgan growth adj day barclay corp
water revenu segment million
non-gaap ep increas y/i buoy top line perform
came ahead expect organ growth currenc
note ep came high end manag guidanc though
includ benefit chang stock-comp increment versu
guidanc due tax benefit relat stock-comp compani tax rate
came expect adjust ep came estim
consensu
water non-gaap ep growth
custom len biopharma result improv easier comp
believ import read quarter biopharma full-year sale
deliv organ growth improv easier comp vs
full-year biopharma increas organ industri end market
full-year sale flat organ y/i moder growth though
difficult comp ta grew organ within full-year
industri increas organ final academ full-year sale grew
organ y/i consist trend challeng quarterli comp
remind segment volatil good read-
coverag given greater instrument exposur govern
exposur within custom class full-year academ increas
growth across geograph end market posit america return
market growth america region grew y/i ex-fx driven strength
organ remind post weaker result
encourag see rebound manag attribut better
perform broad base strength across end market includ healthier spend
mid-cap larg biopharma result eas polici uncertainti europ grew
driven broad base strength across end market manag specif call
servic revenu strength grow instal base driver asia-pacif
region grew quarter led strength china y/i india india
rebound quarter follow disrupt caus implement
gst region
water geograph divers rev
water revenu breakdown end market
gross margin came expect gross margin
y/i q/q full year compani previous guid
investor gross margin note compani hit high end
guidanc gross margin year fx posit top
line given compani pound euro cost exposur like fx headwind
gross margin year
water gross margin adjust ebitda
sg ex-stock comp expens increas y/i revenu
 expens total revenu y/i model
rel steadi expenditur compani continu invest intern growth
water adjust sg trend
adjust oper incom million grew y/i came
estim oper margin y/i
estim fx increas oper expens growth roughli quarter better
expect gross margin lower spend revenu
lower off-set total sg includ stock comp higher
water ebit margin annual growth
compani result show anoth strong quarter free cash
flow gener highlight compani stabl oper oper cash flow
million increas y/i repres adjust net incom
million revenu capit expenditur free cash flow million
quarter repurchas share million result
tax reform compani increas access oversea cash
believ could result acceler capit deploy activ pleas see observ two
detail
water use oper million
 mm except ep reportedincom growth profit ebitda ebit debt pre-tax pre-tax tax net net researchprior yearprior quarter barclay corp
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
